Mankind Pharma has entered a strategic partnership with Denovo Sciences to enhance drug discovery through AI innovation.
This collaboration aims to leverage Mankind Pharma's robust research and development capabilities alongside Denovo Sciences' advanced AI platform for molecular generation and prioritization. By adopting a human-in-the-loop approach, the partnership will ensure that AI-generated candidates are rigorously evaluated and refined by scientific experts throughout the process.
The initiative targets three primary objectives: to shorten the timelines for early drug discovery, to elevate the quality of lead candidates, and to advance only those candidates with the highest potential. By employing computational methods early in the discovery phase, the partners hope to minimize resource expenditure on less viable candidates, ultimately facilitating faster access to effective therapies for patients.
This collaboration signifies Mankind Pharma's commitment to evolving beyond conventional drug discovery techniques. The integration of AI into their R&D strategy represents a pivotal shift, indicating a broader trend in the pharmaceutical industry towards technology-driven innovation in drug development.